A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer

Inhibition of epidermal growth factor receptor (EGFR) signalling contributes to the therapy of colorectal cancer. Gefitinib, an oral EGFR tyrosine kinase inhibitor, shows supra-additive growth inhibition with irinotecan and fluoropyrimidines in xenograft models. We designed a study to determine the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Veronese, M L, Sun, W, Giantonio, B, Berlin, J, Shults, J, Davis, L, Haller, D G, O'Dwyer, P J
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group 2005
Schlagworte:
Short Communication
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361767/
https://ncbi.nlm.nih.gov/pubmed/15870719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602569
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge